{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Davar D"],"funding":["NCI NIH HHS","NIH HHS"],"pagination":["1898-1918.e12"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11560503"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["42(11)"],"pubmed_abstract":["Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses and broad immune activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab in high-risk resectable melanoma. In 31 evaluable patients, 55% major pathologic response (MPR) was observed, meeting primary endpoint. MPR was associated with necrosis, and melanophagocytosis with increased CD8<sup>+</sup> tumor-infiltrating lymphocytes and plasmacytoid dendritic cells (pDCs) in the tumor microenvironment, and increased frequencies of Ki67<sup>+</sup>CD8<sup>+</sup> T cells peripherally. MPRs had an enriched pre-treatment gene signature of myeloid cells, and response to therapy was associated with gene signatures of immune cells, pDCs, phagocytosis, and macrophage activati"],"journal":["Cancer cell"],"pubmed_title":["Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial."],"pmcid":["PMC11560503"],"funding_grant_id":["P50 CA254865","U01 CA268806","P30 CA047904","S10 OD028483","R01 CA257265","U01 CA271407","R01 CA222203"],"pubmed_authors":["McCulloch JA","Kim SW","Krieg AM","O'Toole JP","Sridharan SS","Holtzman MP","Najjar YG","Wang H","Mauro D","Kirkwood JM","Singh J","Trinchieri G","Fury MG","Sun J","Wooldridge J","Fang JR","Dzutsev AK","Duvvuri U","Park HJ","Amatore F","DeBlasio R","Fernandes MR","Morrison RM","Paulovich AG","Jin Y","Pagliano O","Luke JJ","Bobilev D","Das Neves RX","Gao W","Badger JH","Rodrigues RR","Aggarwal P","Chauvin JM","Pingpank JF","Ding Q","Deutsch JS","Zarour HM","Zhao L","Davar D","Urban C","Divarkar P","Whiteaker JR","Hartman DJ","Deitrick C","Taube JM","Bai Y","Cole AM","Groetsch C","Bao R","Rose A","Karunamurthy A","A Choudry H"],"additional_accession":[]},"is_claimable":false,"name":"Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.","description":"Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses and broad immune activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab in high-risk resectable melanoma. In 31 evaluable patients, 55% major pathologic response (MPR) was observed, meeting primary endpoint. MPR was associated with necrosis, and melanophagocytosis with increased CD8<sup>+</sup> tumor-infiltrating lymphocytes and plasmacytoid dendritic cells (pDCs) in the tumor microenvironment, and increased frequencies of Ki67<sup>+</sup>CD8<sup>+</sup> T cells peripherally. MPRs had an enriched pre-treatment gene signature of myeloid cells, and response to therapy was associated with gene signatures of immune cells, pDCs, phagocytosis, and macrophage activati","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-06T15:44:19.644Z","creation":"2026-06-02T03:09:21.859Z"},"accession":"S-EPMC11560503","cross_references":{"pubmed":["39486411"],"doi":["10.1016/j.ccell.2024.10.007"]}}